REDUCING GLOBAL PERIOPERATIVE RISK
This resource center is jointly hosted by The American Journal of Medicine,
The American Journal of Cardiology, and the Canadian Journal of Cardiology.
key Findings
- Therapy was intensified in 43 of 66 patients (65%) who suffered a Troponin I elevation after surgery.
- Patients with a Troponin I elevation who did not receive intensified cardiovascular treatment had a hazard ratio (HR) of 1.77 (95% confidence interval (CI), 1.13–2.42; P = 0.004) for the primary study outcome as compared with the control group.
- In contrast, patients with a Troponin I elevation who received intensified cardiovascular treatment had an HR of 0.63 (95% CI, 0.10–1.19; P = 0.45) for the primary outcome as compared with the control group.
- In patients with elevated Troponin I levels after non-cardiac surgery, long-term adverse cardiac outcomes are likely improved by following evidence-based recommendations for the medical management of acute coronary syndromes, though investigators concluded that this effect needed to be confirmed in a large, randomized, controlled trial.
Key Term:
Tab Section:
Key Column Display :
Left Column
